Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
POL-103A melanoma vaccine in post-resection high-risk melanoma
NCT01546571Phase 3Terminated
- Sponsor
- Polynoma
- Start
- May 2012
- Primary completion
- Apr 2021
- Modality
- Prophylactic Vaccines, Recombinant Proteins and Enzymes, Therapeutic Vaccines
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial in melanoma comparing Placebo with POL-103A (2 arms). Primary endpoints: Recurrence Free Survival, Biological Activity of Seviprotimut-L in Patients With Molecular Weight Range 1 [0,20) at 10 weeks and 11 more. Started May 2012; status: terminated.
02
Drugs
seviprotimut-L
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT01546571.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01546571.